JP2021525758A5 - - Google Patents

Info

Publication number
JP2021525758A5
JP2021525758A5 JP2020566898A JP2020566898A JP2021525758A5 JP 2021525758 A5 JP2021525758 A5 JP 2021525758A5 JP 2020566898 A JP2020566898 A JP 2020566898A JP 2020566898 A JP2020566898 A JP 2020566898A JP 2021525758 A5 JP2021525758 A5 JP 2021525758A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
bladder cancer
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020566898A
Other languages
English (en)
Japanese (ja)
Other versions
JP7335277B2 (ja
JP2021525758A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/034933 external-priority patent/WO2019232392A1/en
Publication of JP2021525758A publication Critical patent/JP2021525758A/ja
Publication of JP2021525758A5 publication Critical patent/JP2021525758A5/ja
Application granted granted Critical
Publication of JP7335277B2 publication Critical patent/JP7335277B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020566898A 2018-06-01 2019-05-31 膀胱がんの治療のための方法 Active JP7335277B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862679495P 2018-06-01 2018-06-01
US62/679,495 2018-06-01
US201962826347P 2019-03-29 2019-03-29
US62/826,347 2019-03-29
PCT/US2019/034933 WO2019232392A1 (en) 2018-06-01 2019-05-31 Methods for the treatment of bladder cancer

Publications (3)

Publication Number Publication Date
JP2021525758A JP2021525758A (ja) 2021-09-27
JP2021525758A5 true JP2021525758A5 (https=) 2022-06-03
JP7335277B2 JP7335277B2 (ja) 2023-08-29

Family

ID=67138025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020566898A Active JP7335277B2 (ja) 2018-06-01 2019-05-31 膀胱がんの治療のための方法

Country Status (11)

Country Link
US (1) US12251394B2 (https=)
EP (1) EP3801561B1 (https=)
JP (1) JP7335277B2 (https=)
KR (1) KR20210015937A (https=)
CN (1) CN112512531B (https=)
AU (1) AU2019277679B2 (https=)
BR (1) BR112020024605A2 (https=)
CA (1) CA3101623A1 (https=)
MX (1) MX2020012964A (https=)
SG (1) SG11202011434SA (https=)
WO (1) WO2019232392A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
JP2024533394A (ja) 2021-09-09 2024-09-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 Stingアゴニストのバイオマーカー及びその使用方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2257704B (en) 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
WO2005089777A1 (en) 2004-03-15 2005-09-29 Karaolis David K R A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
US7592326B2 (en) 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
WO2009133560A1 (en) 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
CN102199183B (zh) 2010-03-26 2013-12-18 北京大学 环二鸟苷酸及其类似物和制备方法
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴThe University Of Chicago 癌処置としてのstingアゴニストの使用
WO2015074145A1 (en) 2013-11-22 2015-05-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
CR20160564A (es) 2014-06-04 2017-01-20 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos como moduladores de sting
EP3546473B1 (en) 2014-12-16 2025-12-10 Kayla Therapeutics Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
US20180344758A1 (en) 2014-12-17 2018-12-06 Lipogen Llc Method of Treating Cancer with cGAMP or cGAsMP
GB201501462D0 (en) * 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
KR102222186B1 (ko) 2015-08-13 2021-03-03 머크 샤프 앤드 돔 코포레이션 Sting 효능제로서 시클릭 디-뉴클레오티드 화합물
JP2018534295A (ja) 2015-10-28 2018-11-22 アドゥロ バイオテック,インク. 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法
CN107849084B (zh) 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
US10723756B2 (en) 2016-01-11 2020-07-28 Innate Tumor Immunity Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
JP2019510802A (ja) 2016-04-07 2019-04-18 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited タンパク質調節物質として有用な複素環アミド
JOP20170188A1 (ar) 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
US20190336615A1 (en) 2017-01-27 2019-11-07 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
US20200055883A1 (en) * 2017-02-17 2020-02-20 Eisai R&D Management Co., Ltd. Cyclic di-nucleotides derivative for the treatment of cancer
WO2018198084A1 (en) 2017-04-27 2018-11-01 Lupin Limited Cyclic di-nucleotide compounds with tricyclic nucleobases
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
AR113224A1 (es) * 2017-04-28 2020-02-19 Novartis Ag Conjugados de anticuerpo que comprenden un agonista de sting
MX2020002303A (es) 2017-08-30 2020-09-10 Beijing Xuanyi Pharmasciences Co Ltd Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon.
WO2019046511A1 (en) 2017-08-31 2019-03-07 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE
US10947263B2 (en) 2017-08-31 2021-03-16 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
KR102812783B1 (ko) 2017-08-31 2025-05-26 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
JP7208225B2 (ja) 2017-08-31 2023-01-18 ブリストル-マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド

Similar Documents

Publication Publication Date Title
JP2021098728A5 (https=)
JP2024133474A5 (https=)
JP2023002662A5 (https=)
JP2020033360A5 (https=)
JP2023512174A5 (https=)
JP2024133475A5 (https=)
JP2016517434A5 (https=)
WO2020102804A3 (en) Pharmaceutical combination for treatment of cancer
JP2016508134A5 (https=)
MX2019012884A (es) Terapia de combinacion.
JP2018109022A5 (https=)
HRP20220718T1 (hr) Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka
JP2015532296A5 (https=)
JP2010527981A5 (https=)
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2014139255A5 (https=)
Cutler et al. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial
JP2018526460A5 (https=)
JP2019515909A5 (https=)
JP2022551691A5 (https=)
JP2019508476A5 (https=)
EP4520394A3 (en) New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases
JP2015516419A5 (https=)
JP2021525758A5 (https=)
MX379191B (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.